Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 06/15/26
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV PreventionBusiness Wire • 06/15/26
The Hormuz Reopening Trade: These 20 Large-Cap Stocks Still Haven't Caught Up To Pre-War LevelsBenzinga • 06/15/26
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak ReliefBusiness Wire • 06/12/26
Pharma and Biotech M&A Boom Accelerates as Companies Expand PipelinesZacks Investment Research • 06/11/26
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community LeadershipBusiness Wire • 06/11/26
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC StudyZacks Investment Research • 06/09/26
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV TreatmentBusiness Wire • 06/08/26
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South AfricaBusiness Wire • 06/05/26
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation PipelineBusiness Wire • 06/04/26
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINEGlobeNewsWire • 06/04/26
GILD Reports Positive Results From Late-Stage Liver Disease StudyZacks Investment Research • 06/03/26
Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)Business Wire • 06/02/26
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference TranscriptSeeking Alpha • 05/29/26
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)Business Wire • 05/27/26